AgenT, founded in 2018, is on a mission to defeat Alzheimer’s by targeting the silent phase. Leveraging a groundbreaking multi-omics approach combined with A.I., they have identified new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they have developed two blood tests, B-HEALED™ and B-AHEAD™, for early and precise detection during the pre-dementia stages, unlocking the future of precision medicine. Their innovation is crucial in the era of emerging treatments like Leqembi, enabling detection and treatment of Alzheimer’s before cognitive decline manifests.

By embracing precision medicine and expanding the biomarker toolkit, AgenT is positioning themselves for the next leap in Alzheimer’s treatment, ensuring patients receive the right therapy at the right time.

Traditional Alzheimer’s tests detect brain amyloid levels—a risk factor, not a definitive diagnostic marker, leading to up to 25% false positives among mild cognitive impairment (MCI) patients. AgenT’s B-HEALED test dramatically reduces this false positive rate by two-thirds with its non-invasive, cost-effective, and scalable blood test, offering a breakthrough in Alzheimer’s diagnostics.

By accurately identifying MCI patients who can benefit from early intervention with disease-modifying treatments, their test ensures timely and precise therapy to slow Alzheimer’s progression effectively, without exposing non-Alzheimer’s patients to unnecessary drug side effects.

–  Therapeutic areas: Alzheimer’s Disease, CNS

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2018